HEMO.L Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 17:25):

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases...

Stats
Dagens volum	1.89M
Gjennomsnittsvolum	16.31M
Markedsverdi	21.27M
EPS	£0 ( 2024-04-25 )
Neste inntjeningsdato	( £0 ) 2024-06-28
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.650
ATR14	£0.0240 (1.45%)

Volum Korrelasjon

Lang: -0.19 (neutral)

Kort: -0.75 (moderate negative)

Signal:(52.56) Neutral

Hemogenyx Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Hemogenyx Pharmaceuticals Korrelasjon - Valuta/Råvare

-0.25
( neutral )

-0.45
( neutral )

0.00
( neutral )

-0.15
( neutral )

0.00
( neutral )

0.42
( neutral )

Hemogenyx Pharmaceuticals Økonomi

Annual	2023
Omsetning:	£0
Bruttogevinst:	£-645 681 (0.00 %)
EPS:	£-0.00600

FY	2023
Omsetning:	£0
Bruttogevinst:	£-645 681 (0.00 %)
EPS:	£-0.00600

FY	2022
Omsetning:	£0
Bruttogevinst:	£-2.60M (0.00 %)
EPS:	£-0.00440

FY	2021
Omsetning:	£0.00
Bruttogevinst:	£-321 230 (0.00 %)
EPS:	£-0.0123

Financial Reports:

No articles found.

Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.